Hans Warrinnier, chief medical officer at Bioxodes, said in a statement that the results are preliminary but all point in the ...

Bioengineering nonprofit Cultivarium is embarking on a three-year journey to develop tools and resources for scientists ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

A new biotech is hitting the Boston scene with $50 million from Flagship Pioneering and a goal of preventing patients from ...

Over the next four months, the Vaccine Integrity Project will hold information-gathering sessions with medical associations, public health organizations, state health officials, vaccine manufacturers, ...

A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in patients with hypertension. | A study of almost 34,000 people in rural China ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost of doing business this year, according to the company’s estim | Boston ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. | Mosaic ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned. | Big Pharma ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...